Oxford Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $597K | Buy |
66,618
+46,401
| +230% | +$416K | 0.22% | 141 |
|
|
2025
Q1 | $152K | Buy |
20,217
+7,052
| +54% | +$52.9K | 0.07% | 383 |
|
|
2024
Q4 | $99K | Buy |
+13,165
| New | +$99K | 0.04% | 390 |
|
|
2018
Q4 | – | Sell |
-98,284
| Closed | -$747K | – | 1778 |
|
|
2018
Q3 | $747K | Sell |
98,284
-102,637
| -51% | -$780K | 0.02% | 1144 |
|
|
2018
Q2 | $1.17M | Sell |
200,921
-129,810
| -39% | -$755K | 0.02% | 945 |
|
|
2018
Q1 | $1.58M | Buy |
330,731
+93,731
| +40% | +$447K | 0.03% | 700 |
|
|
2017
Q4 | $1.21M | Buy |
237,000
+225,428
| +1,948% | +$1.15M | 0.03% | 840 |
|
|
2017
Q3 | $61K | Sell |
11,572
-107,102
| -90% | -$565K | ﹤0.01% | 1491 |
|
|
2017
Q2 | $660K | Buy |
+118,674
| New | +$660K | 0.01% | 1027 |
|
|
2016
Q1 | – | Sell |
-10,598
| Closed | -$110K | – | 799 |
|
|
2015
Q4 | $110K | Sell |
10,598
-222,883
| -95% | -$2.31M | ﹤0.01% | 833 |
|
|
2015
Q3 | $2.66M | Buy |
+233,481
| New | +$2.66M | 0.08% | 247 |
|
|
2014
Q4 | – | Sell |
-208,851
| Closed | -$2.07M | – | 715 |
|
|
2014
Q3 | $2.07M | Sell |
208,851
-84,754
| -29% | -$840K | 0.05% | 365 |
|
|
2014
Q2 | $3.73M | Buy |
+293,605
| New | +$3.73M | 0.12% | 241 |
|